Jazz Pharmaceuticals (JAZZN) Ratios
Jazz Pharmaceuticals Ratios
MX:JAZZN's free cash flow for Q2 2026 was $397.60M. For the 2026 fiscal year, MX:JAZZN's free cash flow was decreased by $-18.10M and operating cash flow was $415.70M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.86 | 4.46 | 2.24 | 2.79 | 3.23 |
| Quick Ratio | 1.67 | 3.99 | 1.85 | 2.03 | 1.90 |
| Cash Ratio | 0.62 | 2.32 | 0.98 | 0.94 | 0.73 |
| Solvency Ratio | 0.05 | 0.15 | 0.14 | 0.05 | 0.03 |
| Operating Cash Flow Ratio | 0.60 | 1.34 | 0.71 | 1.36 | 0.96 |
| Short-Term Operating Cash Flow Coverage | 1.32 | 45.03 | 1.81 | 41.03 | 25.11 |
| Net Current Asset Value | $ -3.17B | $ -3.29B | $ -4.22B | $ -5.14B | $ -5.72B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.47 | 0.51 | 0.51 | 0.54 | 0.50 |
| Debt-to-Equity Ratio | 1.26 | 1.51 | 1.55 | 1.88 | 1.55 |
| Debt-to-Capital Ratio | 0.56 | 0.60 | 0.61 | 0.65 | 0.61 |
| Long-Term Debt-to-Capital Ratio | 0.50 | 0.60 | 0.58 | 0.65 | 0.60 |
| Financial Leverage Ratio | 2.70 | 2.93 | 3.05 | 3.51 | 3.10 |
| Debt Service Coverage Ratio | 0.44 | 5.99 | 1.75 | 5.10 | 2.62 |
| Interest Coverage Ratio | 1.15 | 3.01 | 2.00 | -0.23 | 0.61 |
| Debt to Market Cap | 0.52 | 0.80 | 0.73 | 0.57 | 0.80 |
| Interest Debt Per Share | 92.14 | 103.50 | 96.08 | 97.54 | 107.74 |
| Net Debt to EBITDA | 15.34 | 2.46 | 2.96 | 3.36 | 5.41 |
| Profitability Margins | |||||
| Gross Profit Margin | 88.21% | 89.05% | 88.64% | 85.23% | 85.76% |
| EBIT Margin | -10.16% | 21.18% | 21.14% | 22.93% | 15.36% |
| EBITDA Margin | 6.16% | 37.40% | 37.80% | 40.13% | 33.21% |
| Operating Profit Margin | 5.26% | 17.61% | 15.09% | -1.79% | 5.50% |
| Pretax Profit Margin | -14.73% | 11.52% | 7.69% | -10.46% | -3.67% |
| Net Profit Margin | -8.35% | 13.77% | 10.82% | -6.12% | -10.63% |
| Continuous Operations Profit Margin | -8.35% | 13.77% | 10.82% | -6.12% | -10.65% |
| Net Income Per EBT | 56.66% | 119.51% | 140.66% | 58.55% | 289.69% |
| EBT Per EBIT | -280.09% | 65.40% | 50.97% | 584.03% | -66.69% |
| Return on Assets (ROA) | -3.05% | 4.66% | 3.64% | -2.07% | -2.67% |
| Return on Equity (ROE) | -8.25% | 13.68% | 11.10% | -7.26% | -8.30% |
| Return on Capital Employed (ROCE) | 2.38% | 6.53% | 5.87% | -0.66% | 1.48% |
| Return on Invested Capital (ROIC) | 1.22% | 6.50% | 5.52% | -0.39% | 1.48% |
| Return on Tangible Assets | -6.59% | 10.11% | 9.83% | -6.69% | -9.91% |
| Earnings Yield | -3.44% | 7.36% | 5.33% | -2.25% | -4.33% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.14 | 5.68 | 5.43 | 5.62 | 5.49 |
| Payables Turnover | 4.12 | 5.72 | 4.24 | 5.96 | 4.39 |
| Inventory Turnover | 1.21 | 0.93 | 0.73 | 0.76 | 0.41 |
| Fixed Asset Turnover | 16.49 | 17.93 | 16.32 | 12.14 | 9.01 |
| Asset Turnover | 0.37 | 0.34 | 0.34 | 0.34 | 0.25 |
| Working Capital Turnover Ratio | 1.55 | 1.48 | 2.15 | 2.11 | 1.55 |
| Cash Conversion Cycle | 284.92 | 393.97 | 481.39 | 485.89 | 871.73 |
| Days of Sales Outstanding | 71.05 | 64.30 | 67.19 | 64.98 | 66.45 |
| Days of Inventory Outstanding | 302.39 | 393.44 | 500.30 | 482.19 | 888.34 |
| Days of Payables Outstanding | 88.52 | 63.77 | 86.10 | 61.29 | 83.06 |
| Operating Cycle | 373.44 | 457.74 | 567.49 | 547.17 | 954.79 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 22.23 | 22.57 | 17.25 | 20.34 | 13.04 |
| Free Cash Flow Per Share | 18.79 | 21.80 | 16.88 | 12.37 | 12.28 |
| Dividend Paid and CapEx Coverage Ratio | 6.46 | 29.04 | 45.57 | 2.55 | 17.10 |
| Capital Expenditure Coverage Ratio | 6.46 | 29.04 | 45.57 | 2.55 | 17.10 |
| Operating Cash Flow Coverage Ratio | 0.25 | 0.23 | 0.19 | 0.22 | 0.13 |
| Operating Cash Flow to Sales Ratio | 0.32 | 0.34 | 0.28 | 0.35 | 0.25 |
| Free Cash Flow Yield | 11.05% | 17.70% | 13.72% | 7.77% | 9.64% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -29.11 | 13.59 | 18.77 | -44.47 | -23.12 |
| Price-to-Sales (P/S) Ratio | 2.43 | 1.87 | 2.03 | 2.72 | 2.46 |
| Price-to-Book (P/B) Ratio | 2.40 | 1.86 | 2.08 | 3.23 | 1.92 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.05 | 5.65 | 7.29 | 12.88 | 10.38 |
| Price-to-Operating Cash Flow Ratio | 7.65 | 5.46 | 7.13 | 7.83 | 9.77 |
| Price-to-Earnings Growth (PEG) Ratio | 0.18 | 0.35 | -0.07 | 1.27 | 0.10 |
| Enterprise Value Multiple | 54.80 | 7.47 | 8.33 | 10.14 | 12.81 |
| Enterprise Value | 14.40B | 11.36B | 12.07B | 14.89B | 13.17B |
| EV to EBITDA | 54.80 | 7.47 | 8.33 | 10.14 | 12.81 |
| EV to Sales | 3.37 | 2.79 | 3.15 | 4.07 | 4.26 |
| EV to Free Cash Flow | 12.56 | 8.43 | 11.30 | 19.25 | 17.96 |
| EV to Operating Cash Flow | 10.62 | 8.14 | 11.05 | 11.71 | 16.91 |
| Tangible Book Value Per Share | -31.82 | -38.46 | -54.26 | -70.38 | -84.01 |
| Shareholders’ Equity Per Share | 70.81 | 66.20 | 59.04 | 49.34 | 66.43 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.43 | -0.20 | -0.41 | 0.41 | -1.90 |
| Revenue Per Share | 69.98 | 65.80 | 60.58 | 58.51 | 51.83 |
| Net Income Per Share | -5.84 | 9.06 | 6.55 | -3.58 | -5.51 |
| Tax Burden | 0.57 | 1.20 | 1.41 | 0.59 | 2.90 |
| Interest Burden | 1.45 | 0.54 | 0.36 | -0.46 | -0.24 |
| Research & Development to Revenue | 0.18 | 0.22 | 0.22 | 0.16 | 0.16 |
| SG&A to Revenue | 0.42 | 0.34 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 |
| Income Quality | -3.81 | 2.49 | 2.63 | -5.68 | -2.36 |
Currency in USD